Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Zacks Analyst Blog Highlights: Genomic Health, Teva Pharmaceuticals, Omnicom, MCG Capital and Merrill Lynch
- CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Genomic Health Inc. (Nasdaq: GHDX), Teva Pharmaceuticals (Nasdaq: TEVA), Omnicom Group...
- Research articles 2008-04-24
- flexSCANs Banks Visits the CEOCorner.
- M2 PRESSWIRE-11 August 2006-InvestSource Inc.: flexSCANs Banks Visits the CEOCornerC1994-2006 M2 COMMUNICATIONS LTD RDATE:11082006 Stocks in the News: InvestSource Communications, Inc. (OTC: IVSR), flexSCAN, Inc. (OTC: FXSC), Medicure Inc. (AMEX: MCU), MGI Pharma Inc. (NASDAQ: MOGN), Merck & Co Inc. (NYSE:...
- Research articles 2006-08-11
- Stamford, Conn., Maker of OxyContin Cuts Work Force by One-Third.
- By Julie Fishman-Lapin, The Stamford Advocate, Conn. Knight Ridder/Tribune Business News Apr. 14--STAMFORD, Conn. -- Purdue Pharma slashed 291 jobs in the city yesterday, cutting its local work force by almost a third, as the drug company tries to shore up its...
- Research articles 2004-04-14
- Two Drugmakers Win FDA Approval to Make Generic Version of Oxycontin.
- By Linda Loyd, The Philadelphia Inquirer Knight Ridder/Tribune Business News Mar. 25--Two pharmaceutical companies with major operations in the Philadelphia area have won regulatory approval to sell generic versions of the potent painkiller OxyContin, a drug that helps patients with severe...
- Research articles 2004-03-25
- Generic Remeron
- Teva Pharmaceuticals USA has introduced mirtazapine tablets, AB rated and bioequivalent to Remeron (N.V. Organon). The product is available in 30-count bottles of 15 and 30 mg.
- Research articles 2003-02-17
- Generic Versions of Verelan Debut
- NEW YORK--The Food and Drug Administration has given several generic drug manufacturers approval to market versions of the hypertension drug Verelan verapamil. Irish drug maker Elan Corp. acquired Verelan in September from American Home Products Corp. The drug has annual U.S. sales of $90 million. Among those receiving...
- Research articles 1999-07-19
- Shire gains as investors seek panacea
- Drugmakers found favour on Monday as the FTSE 100 followed world markets with its sharpest fall in six weeks. Shire led the index, rising 2.2 per cent to £10.19 as investors sought safety in defensive sectors. Takeover hopes also played a part, with Shire up 15 per cent in a...
- News items 2009-08-17
- Teva Pharmaceuticals Q3 2006 Earnings Call Transcript
- Earnings Call Excerpt Teva Pharmaceuticals TEVA Q3 2006 Earnings Call November 7, 2006 8:45 am ET Executives: Israel Makov, President and Chief Executive Officer Moshe Manor, Group Vice President, Global Products Dan Suesskind, CFO William Marth, President & CEO, Teva Pharmaceuticals...
- Earnings calls 2006-11-07
- Teva to Lay Off 1,000; Croatian Staff to Get Generous Severances
- Teva Pharmaceuticals is to lay off 1,000 or more employees worldwide as part of its acquisition of Barr Pharmaceuticals. Three hundred of those layoffs will be in at Teva's IVAX plant in DOral, Fla., according to the Miami Herald. Those workers may be wishing they were Croatian,...
- Blog posts 2009-02-13
- FTC Eyes Supply Dispute Between Drugmakers
- The Federal Trade Commission is concerned that some brand-name drugmakers are declining to supply some bulk ingredients to their generic rivals which, of course, want to use materials to make copies of more expensive meds, The Wall Street Journal writes. Meanwhile, GlaxoSmithKline cites a federal drug-safety program as its reason...
- News items 2009-11-13
Additional Resources
- Teva-Hoechst Copaxone deal.(Teva Pharmaceuticals and Hoechst Marion Roussel will jointly distribute Teva's Copaxone multiple sclerosis equipment)
- Teva Pharmaceuticals has announced the signing of a strategic cooperation agreement with German pharmaceutical giant Hoechst Marion Roussel regarding the joint distribution of Teva's Copaxone multiple sclerosis treatment. Teva Pharmaceuticals has announced the signing of a strategic cooperation agreement with German pharmaceutical giant Hoechst...
- Research articles 1995-12-31
- Teva to Hungary. (Teva Pharmaceuticals to establish a Hungarian subsidiary)
- Teva Pharmaceuticals will establish a subsidiary in Hungary at an investment of approximately $1 million. The new company, scheduled to open within a few weeks, will market Teva's products in Hungary and other countries in ... Teva Pharmaceuticals will establish a subsidiary in Hungary...
- Research articles 1993-03-26
- Teva looks to raise $100. in bonds. (Teva Pharmaceuticals)
- Teva Pharmaceuticals is set to raise over $100 million in the first half of the year through a concern bond issue. The European investment bank, Societe Generale, said that Teva has already applied to a number of leading rating companies as a prepar Teva Pharmaceuticals...
- Research articles 1997-01-18
- Teva gets Canadian Copaxone approval. (marketing approval, Teva Pharmaceuticals)
- Teva Pharmaceuticals (Nasdaq: TEVIY) has received approval to market its multiple sclerosis MS treatment, Copaxone, in Canada. The decision, which generated an immediate 4.3 percent ... Teva Pharmaceuticals (Nasdaq: TEVIY) has received approval to market its multiple sclerosis MS treatment, Copaxone, in Canada....
- Research articles 1997-09-15
- Gronthal offers strong Teva buy word. (Teva Pharmaceuticals stock)
- U.S. brokerage organization, Gronthal, has published a strong buy rating for the Teva Pharmaceuticals share, setting a new unit target price of $94 - 45 percent higher than the stock's current Wall Street trading value of $64.5. The broker's upgrade U.S. brokerage organization, Gronthal, has...
- Research articles 1997-07-31
- Teva returns "higher than expected" income. (for the first quarter 1997, Teva Pharmaceuticals)
- Teva Pharmaceuticals (Nasdaq: TEVIY) posted a higher-than-expected operating income total for the first quarter of the year, at $45.4 million, compared with Lehman Brothers' estimate of $41.7 million. A spokesperson for the US investment house attri Teva Pharmaceuticals (Nasdaq: TEVIY) posted a higher-than-expected operating...
- Research articles 1997-05-31
- Copaxone maintains Teva optimism.(Teva Pharmaceuticals)
- At a recent meeting with analysts and investors in Israel, Teva Pharmaceuticals management reviewed the clinical trials currently taking place on its multiple sclerosis MS treatment, Copaxone, the results of which are expected to enhance the produ At a recent meeting with analysts and investors...
- Research articles 1997-07-15
- Teva makes waves on Wall Street. (Teva Pharmaceuticals)
- The middle of the month saw Teva Pharmaceuticals ride the crest of a wave, along with several other Israeli companies -- including NICE Systems, Checkpoint and Teledata. The middle of the month saw Teva Pharmaceuticals ride the crest of a wave, along with...
- Research articles 1996-09-25
- More FDA approvals for Teva. (Food and Drug Administration approves Teva Pharmaceuticals marketing of generic anti-histamine drug)
- Lemmon the U.S. subsidiary of Teva Pharmaceuticals has received approval of the FDA to market a generic anti-histamine drug in the U.S. The total market of the drug is estimates to be some $25 million annually. A generic drug is one whose original 10 Lemmon the...
- Research articles 1992-02-07
- Ranbaxy, Teva Pharmaceuticals and Andrx in Legal Battles.(Brief Article)
- RANBAXY, TEVA Pharmaceuticals and Andrx moved forward in litigation to bring generic products to market. Last week, Ranbaxy Pharmaceuticals Inc. USA, a subsidiary of Ranbaxy Laboratories Ltd., reported a federal appeals court vacated a prelim RANBAXY, TEVA Pharmaceuticals...
- Research articles 2001-08-20
- << Previous
- page 1 of 1
- Next >>
